Provided by Tiger Trade Technology Pte. Ltd.

Global X Aging Population ETF

36.05
+0.10150.28%
Volume:835
Turnover:30.04K
Market Cap:87.60M
PE:- -
High:36.05
Open:35.94
Low:35.94
Close:35.94
52wk High:39.48
52wk Low:33.59
Shares:2.43M
Float Shares:2.43M
Volume Ratio:1.34
T/O Rate:0.03%
Dividend:0.33
Dividend Rate:0.91%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Taking Ozempic? a Routine Eye Exam Could Help You Understand Your Risk for Vision Loss

Dow Jones
·
Sep 28

Autagco to Close Key Pergam Assisted Living Facility After Property Sale

TIPRANKS
·
Sep 28

FDA Approves AbbVie’s JUVMO for Adults with Parkinson’s Disease

Reuters
·
Sep 28

U.S. FDA Approves Abbvie's Juvmo™ (Tavapadon) for Parkinson's Disease

THOMSON REUTERS
·
Sep 28

Abbvie - Juvmo Expected to be Available in the U.S. in October 2026

THOMSON REUTERS
·
Sep 28

Eli Lilly price target raised to $1,500 from $1,400 at JPMorgan

TIPRANKS
·
Sep 28

Lilly Launches Initiative to Expand Diabetes, Obesity Drug Access

MT Newswires Live
·
Sep 28

Eli Lilly launches ‘Lilly Change the Course Commitment’

TIPRANKS
·
Sep 28

Eli Lilly - to Register Diabetes and Obesity Medicines in Lmics and Expand Access

THOMSON REUTERS
·
Sep 28

Eli Lilly - Aims to Treat Equal Number of Patients in Lmics and High-Income Countries by 2040

THOMSON REUTERS
·
Sep 28

JPMorgan Adjusts Price Target on Eli Lilly to $1,500 From $1,400, Maintains Overweight Rating

MT Newswires Live
·
Sep 28

Eli Lilly's Olumiant Gets FDA Approval for Severe Alopecia Areata in Adolescents

MT Newswires Live
·
Sep 28

Healthcare Shows Resilience! Pharma ETF Huabao (562050) Rises Against the Market, Livzon Pharmaceutical Group Hits Limit Up! Medical Devices Show Localized Strength, Mindray and United Imaging Advance Together

Deep News
·
Sep 28

Nektar selloff on trial brings ‘strong entry point,’ says BTIG

TIPRANKS
·
Sep 28

US FDA Approves AbbVie's Drug for Parkinson's Disease

Reuters
·
Sep 26

US FDA - Approves Juvmo (Tavapadon) for Parkinson’s Disease in Adults on Sept 25, 2026

THOMSON REUTERS
·
Sep 26

Eli Lilly Gets Expanded Label Approval from FDA for Alopecia Drug

Dow Jones
·
Sep 26

FDA Approves Lilly's Olumiant (Baricitinib) for Pediatric Patients 12 Years of Age and Older with Severe Alopecia Areata

THOMSON REUTERS
·
Sep 26

ADARx Pharmaceuticals Shares Soar in NASDAQ Debut After Upsized IPO

Reuters
·
Sep 26

Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case

MT Newswires Live
·
Sep 26